Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614001098628
Ethics application status
Approved
Date submitted
10/10/2014
Date registered
16/10/2014
Date last updated
14/09/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a single oral dose of ipratropium bromide in healthy male and female volunteers with and without concurrent oral charcoal blockade.
Scientific title
A single dose, randomized, open label, crossover comparative bioavailability study of ipratropium bromide in healthy male and female volunteers under fasting conditions with and without concurrent oral charcoal blockade.
Secondary ID [1] 285478 0
None
Universal Trial Number (UTN)
U1111-1162-4250
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bioavailability study conducted in healthy volunteers comparing ipratropium bromide administered with and without concurrent charcoal dosing with no health condition or problem studied.

Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, ipratropium bromide belongs to a class of medicines called synthetic ammonium antimuscainic bronchodilators. It is used for the treatment of bronchospasm associated with COPD, including bronchitis and emphysema. 293256 0
Condition category
Condition code
Other 293527 293527 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, crossover study design whereby each participant receives the formulation of ipratropium bromide (1 x 500 mcg) on one occasion with oral charcoal administered pre-dose and at specified times up to 4 hours post dosing and on one occasion without oral charcoal with each dose separated by a one week washout period. The intervention for this trial is ipratropium bromide with charcoal.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose).
Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose.

Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance and will be monitored and for 24 hours after dosing.

Standard meals will be consumed at the Clinical Site with no additional food intake allowed.

Vital sign examination, assessment of well-being, alcohol breath testing, drug testing and pregnancy testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.

Pre and post study laboratory tests will be completed to assess the healthy of participants along with HIV, Hepatitis and drugs of abuse testing.

The volunteer's randomsied to receive 50 ml of activated charcoal suspension will be given the charcoal suspension 2 minutes prior to dosing, immediately with dosing and also at 1, 2 and 4 hours post dosing.

Each dose (1 x 500 mcg) will be taken orally as 2 ml of ipratropium bromide solution in 18 ml of water. Medication will be administered via a 30 ml syringe and a mouth check will be conducted to ensure the medication has been taken as directed.
Intervention code [1] 290416 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover study design whereby each participant receives ipratropium bromide (1 x 500 mcg) with concurrent oral charcoal on one occasion and ipratropium bromide (1 x 500 mcg) on one occasion without oral charcoal with each dose separated by a one week washout period. The comparator/control for this trial is ipratropium bromide without charcoal.
Control group
Active

Outcomes
Primary outcome [1] 293346 0
To compare the bioavailability of ipratropium bromide (as summarised by Cmax and AUC) with and without concurrent oral charcoal. All plasma samples will be assayed for ipratropium bromide using one fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 293346 0
0, 0.08, 0.17, 0.25, 0.33, 0.42, 0.50, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 18 and 24 hours
Secondary outcome [1] 310825 0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 310825 0
0, 0.08, 0.17, 0.25, 0.33, 0.42, 0.50, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 18 and 24 hours

Eligibility
Key inclusion criteria
Healthy male and non-pregnant females
Aged between 18 and 45
Non-smoker
BMI between 18.5 and 30 inclusive
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure, pulse, heart rate, temperature, well-being assessment and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any history of COPD, chronic bronchitis, emphysema, asthma , or any other lung disease, recent upper or lower respiratory tract infection, migraine headaches
Concomitant drug therapy of any kind
Who have taken any drug that induces/inhibits the hepatic microsomal enzymes within 30 days prior to dosing
Who have received an investigational compound or drug known to induce or inhibit liver enzymes within 60 days of the start of the study
Sensitivity to ipratropium bromide any other similar class medicines or the excipients of ipratropium bromide
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are pregnant and/or are breastfeeding
Who are planning to start a family within 60 days of receiving the final dose.
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identification of each treatment will only be known to the Managing Director and the Section Head - Trials and Regulatory Affairs.

Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation list will be prepared using a computer program for a balanced two-way crossover design.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-availability
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
24/10/2014
Actual
30/10/2014
Date of last participant enrolment
Anticipated
Actual
31/10/2014
Date of last data collection
Anticipated
Actual
Sample size
Target
24
Accrual to date
Final
24
Recruitment outside Australia
Country [1] 6405 0
New Zealand
State/province [1] 6405 0
Otago

Funding & Sponsors
Funding source category [1] 290079 0
Commercial sector/Industry
Name [1] 290079 0
Cipla Ltd
Country [1] 290079 0
India
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corporation Limited
Address
156 Frederick Street
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 288774 0
None
Name [1] 288774 0
Address [1] 288774 0
Country [1] 288774 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291785 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 291785 0
Ministry of Health
1 the Terrace
PO Box 5013
Wellington 6145
Ethics committee country [1] 291785 0
New Zealand
Date submitted for ethics approval [1] 291785 0
02/10/2014
Approval date [1] 291785 0
20/10/2014
Ethics approval number [1] 291785 0
14/STH/150

Summary
Brief summary
The objective of this study is to evaluate the bioavailability of ipratropium bromide in healthy male and female volunteers under fasting conditions with and without concurrent oral charcoal.
Trial website
Trial related presentations / publications
No presentations or citations available. Final CSR provided to Sponsor Company for Registration Purposes
Public notes

Contacts
Principal investigator
Name 52030 0
Dr Noelyn Hung
Address 52030 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 52030 0
New Zealand
Phone 52030 0
+6434779669
Fax 52030 0
+6434779605
Email 52030 0
noelyn.hung@otago.ac.nz
Contact person for public queries
Name 52031 0
Mrs Linda Folland
Address 52031 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 52031 0
New Zealand
Phone 52031 0
+6434779669
Fax 52031 0
+6434779605
Email 52031 0
linda.folland@zenithtechnology.co.nz
Contact person for scientific queries
Name 52032 0
Dr Cheung Tak Hung
Address 52032 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 52032 0
New Zealand
Phone 52032 0
+6434779669
Fax 52032 0
+6434779605
Email 52032 0
tak.hung@zenithtechnology.co.nz

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.